Bartlett et al., 2019 - Google Patents
The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antiviralsBartlett et al., 2019
View PDF- Document ID
- 4315003124605000535
- Author
- Bartlett S
- Yu A
- Chapinal N
- Rossi C
- Butt Z
- Wong S
- Darvishian M
- Gilbert M
- Wong J
- Binka M
- Alvarez M
- Tyndall M
- Krajden M
- Janjua N
- Publication year
- Publication venue
- Liver International
External Links
Snippet
Background Population‐level monitoring of hepatitis C virus (HCV) infected people across cascades of care identifies gaps in access and engagement in care and treatment. We characterized the population‐level care cascade for HCV in British Columbia (BC), Canada …
- 208000005176 Hepatitis C 0 title description 6
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
- G06Q50/24—Patient record management
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bartlett et al. | The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals | |
Lim et al. | Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis | |
Witkiewitz et al. | Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder | |
Jacobs et al. | Gene-environment interactions in multiple sclerosis: a UK Biobank study | |
Stepanova et al. | Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity | |
Donnelly et al. | Acute liver failure in Scotland: changes in aetiology and outcomes over time (the Scottish Look‐Back Study) | |
Fu et al. | Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study | |
Grint et al. | Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA | |
Papatheodoridis et al. | Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review | |
Sonmez et al. | Clinical characteristics and outcomes of COVID‐19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia) | |
Garg et al. | Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center | |
Huang et al. | Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation‐wide cohort study | |
Chiang et al. | Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers | |
Darvishian et al. | Loss to follow‐up: a significant barrier in the treatment cascade with direct‐acting therapies | |
Kim et al. | Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients | |
Bader et al. | A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients | |
Aviani et al. | Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID‐19) treatment: A systematic review and meta‐analysis based on recent studies and previous respiratory pandemics | |
Chen et al. | A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease | |
Liu et al. | Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID‐19 patients with hypertension in Wuhan: a hospital‐based retrospective cohort study | |
Pham et al. | Sustained virologic response and costs associated with direct-acting antivirals for chronic hepatitis C infection in Oklahoma Medicaid | |
Berenguer et al. | Identification of liver fibrosis in HIV/HCV‐coinfected patients using a simple predictive model based on routine laboratory data | |
Garcia‐Tsao | Can we rely on changes in HVPG in patients with cirrhosis? | |
Rossi et al. | Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care | |
Zhou et al. | Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease | |
Korkmaz et al. | Assessment of evidence for positive association and seroprevalence of hepatitis B and C in diabetic patients in a developing country |